ATE494000T1 - Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs - Google Patents

Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs

Info

Publication number
ATE494000T1
ATE494000T1 AT03714791T AT03714791T ATE494000T1 AT E494000 T1 ATE494000 T1 AT E494000T1 AT 03714791 T AT03714791 T AT 03714791T AT 03714791 T AT03714791 T AT 03714791T AT E494000 T1 ATE494000 T1 AT E494000T1
Authority
AT
Austria
Prior art keywords
human cancer
egfr transactivation
inhibitors
egfr
transactivation inhibitors
Prior art date
Application number
AT03714791T
Other languages
English (en)
Inventor
Axel Ullrich
Beatrix Schaefer
Oliver Fischer
Andreas Gschwind
Michael Leserer
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27798783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494000(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE494000T1 publication Critical patent/ATE494000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03714791T 2002-03-08 2003-03-07 Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs ATE494000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02005452 2002-03-08
PCT/EP2003/002361 WO2003075947A1 (en) 2002-03-08 2003-03-07 Use of egfr transactivation inhibitors in human cancer

Publications (1)

Publication Number Publication Date
ATE494000T1 true ATE494000T1 (de) 2011-01-15

Family

ID=27798783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03714791T ATE494000T1 (de) 2002-03-08 2003-03-07 Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs

Country Status (8)

Country Link
US (1) US20050176633A1 (de)
EP (2) EP2305284A3 (de)
AT (1) ATE494000T1 (de)
AU (2) AU2003219029B2 (de)
CA (1) CA2477932A1 (de)
DE (1) DE60335609D1 (de)
ES (1) ES2359136T3 (de)
WO (1) WO2003075947A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
JP2003520195A (ja) * 1999-05-14 2003-07-02 イムクローン システムズ インコーポレイティド 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
NZ252486A (en) * 1992-04-29 1997-08-22 Univ Georgetown Blocking peptides capable of binding to ligands of the epidermal growth factor receptor (erbb-2) and their use in detecting such ligands
US6562596B1 (en) * 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
JP2003520195A (ja) * 1999-05-14 2003-07-02 イムクローン システムズ インコーポレイティド 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
WO2000077195A1 (en) * 1999-06-09 2000-12-21 Biopharm Gesellschaft Zur Biotechnologischen Entw Icklung Und Zum Vertrieb Von Pharmaka Mbh Nucleic acid encoding novel egf-like growth factors
AU779298B2 (en) 1999-08-16 2005-01-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor
WO2001035899A2 (en) * 1999-11-19 2001-05-25 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
NZ516873A (en) * 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
FR2828104B1 (fr) * 2001-08-01 2005-06-24 Chu Montpellier Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome
CA2591659A1 (en) * 2004-12-17 2006-06-22 Monash University Regulation of metalloprotease cleavage of cell surface proteins

Also Published As

Publication number Publication date
DE60335609D1 (de) 2011-02-17
CA2477932A1 (en) 2003-09-18
AU2008249216B2 (en) 2012-01-19
AU2008249216A1 (en) 2008-12-18
ES2359136T3 (es) 2011-05-18
EP2305284A3 (de) 2012-11-14
US20050176633A1 (en) 2005-08-11
EP1482964A1 (de) 2004-12-08
WO2003075947A1 (en) 2003-09-18
AU2003219029A1 (en) 2003-09-22
AU2003219029B2 (en) 2008-09-11
EP1482964B1 (de) 2011-01-05
EP2305284A2 (de) 2011-04-06

Similar Documents

Publication Publication Date Title
DE60212801D1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
ATE381557T1 (de) Rho-kinase inhibitoren
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
ATE540962T1 (de) Extraktive verfahren zur aufreinigung von sucralose
BRPI0820000A2 (pt) Derivados de 1,2-dissubstituído-4 benzilamino-pirrolidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
MY134783A (en) Rho-kinase inhibitors
DE60321130D1 (de) Variation von parametern zur neurostimulation
TW200621230A (en) Anti-tumor compounds
CY1112888T1 (el) Μεθοδος παρασκευης της (s)-παντοπραζολης
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
ATE494000T1 (de) Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
CY1109399T1 (el) Υποκατεστημενα διφαινυλ καρβοξυλικα οξεα και παραγωγα αυτων
DE502005009919D1 (de) Verwendung von polysilazanen zur beschichtung von metallbändern
ATE361745T1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
BR0309708A (pt) Compostos como moduladores de receptor de opióde
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
DE602007010459D1 (de) Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE314043T1 (de) Derivate von aza-spiroverbindungen zur behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties